Vaxcyte was founded by Grant Pickering.

Who are Vaxcyte's investors?

Vaxcyte's investors include BioRock Ventures, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Longitude Capital, Pivotal Life Sciences, RA Capital, Dolby Family Ventures and 2 more.

Vaxcyte

NASDAQ: PCVX

10 known investors

Find your way into Vaxcyte

Paths you didn't know you had: your email and LinkedIn already hold routes to the Vaxcyte team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates. Founded in 2013, it uses a cell-free protein synthesis platform to engineer vaccines for children and adults.

Biotech Healthtech

Founders & leadership

Grant PickeringCo-Founder, CEO, DirectorFounder of Vaxcyte, which develops vaccines to prevent bacterial infections using a cell-free protein synthesis platform. He has held leadership roles in the development and commercialization of several life science products, including Provenge, Flonase, Victrio, and Zelnate, with experience in biopharmaceutical commercialization, clinical development, fundraising, and corporate development.

Jeff FairmanVice President of Research and Co-Founder

Investors · 10

BioRock Ventureslisted by BioRock VenturesSan Franciscovia Mary Wheeler · inferred

How we know: BioRock Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

CTI Life Sciences Fund L.P.listed by CTI Life Sciences Fund L.P.Montréal

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

How we know: Frazier Life Sciences's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us

Dolby Family VenturesreportedSan Francisco

How we know: a partner's Signal profile · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: the S-1 prospectus · Not right? Tell us

MedicxireportedLondon

How we know: the S-1 prospectus · Not right? Tell us

Valuation · disclosed

Disclosed events

$774.2Mvaluation at IPOJun 2020 · $16.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 2

DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.

VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.

Companies working in the same space as Vaxcyte.

In the news

Vaxcyte to Participate in Upcoming Investor Conferences | The Manila Timesmanilatimes.net · Aug 2026

Frequently asked questions

What does Vaxcyte do?: Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates. Founded in 2013, it uses a cell-free protein synthesis platform to engineer vaccines for children and adults.
Who founded Vaxcyte?: Vaxcyte was founded by Grant Pickering.
Who are Vaxcyte's investors?: Vaxcyte's investors include BioRock Ventures, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Longitude Capital, Pivotal Life Sciences, RA Capital, Dolby Family Ventures and 2 more.